Merck & Co., Inc. $MRK Holdings Decreased by R.H. Dinel Investment Counsel Inc.

R.H. Dinel Investment Counsel Inc. reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 29.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,365 shares of the company’s stock after selling 13,377 shares during the period. Merck & Co., Inc. accounts for approximately 2.4% of R.H. Dinel Investment Counsel Inc.’s holdings, making the stock its 15th biggest position. R.H. Dinel Investment Counsel Inc.’s holdings in Merck & Co., Inc. were worth $3,301,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Darwin Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after purchasing an additional 216 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Barnes Dennig Private Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares in the last quarter. Bare Financial Services Inc lifted its stake in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after purchasing an additional 125 shares during the last quarter. Finally, United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. during the third quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a US$6.7B acquisition of Terns Pharmaceuticals to add TERN-701 (an investigational oral CML therapy) to its oncology/hematology pipeline—a clear move to build revenue and R&D options ahead of Keytruda’s planned 2028 exclusivity loss. Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition
• Positive Sentiment: RBC reiterated an Outperform and kept a $142 price target after Merck’s Terns call, signaling sell‑side support for the strategy despite questions about the transaction premium. RBC Reiterates Merck (MRK) Outperform
• Positive Sentiment: Agilent won FDA approval for the PD‑L1 22C3 companion diagnostic in esophageal/GEJ carcinoma, which can help identify patients for Keytruda treatment—supportive for near‑term uptake in that indication. Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer) and option/trade ideas targeting MRK indicate elevated investor interest and constructive conviction in Merck as a defensive large‑cap pharma. Jim Cramer on Merck & Co.
• Neutral Sentiment: Analyst model tweaks are minor: Erste marginally raised FY2026 EPS estimates (from $5.12 to $5.13), reflecting limited near‑term changes to consensus earnings expectations. MarketBeat analyst update
• Neutral Sentiment: Coverage pieces note Merck has outperformed recently (stock up ~50% over six months); some articles offer tactical trade ideas (options/covered calls) that reflect market momentum rather than fundamental shifts. Merck Stock Soars 50% in 6 Months
• Negative Sentiment: Keytruda’s planned 2028 loss of exclusivity remains the central long‑term risk—analysts and articles stress patent cliff exposure and some weak vaccine sales, which temper valuation upside. Zacks: Merck Stock Soars 50% in 6 Months
• Negative Sentiment: The proposed Terns transaction may face rival interest and is the subject of a shareholder‑lawyer investigation (Kahn Swick & Foti), introducing deal execution, regulatory and legal risk that could delay or change terms. MSN: Merck’s Terns acquisition may face rival interest BusinessWire: KSF Investigation

Insider Activity at Merck & Co., Inc.

In other news, CFO Caroline Litchfield sold 41,997 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the transaction, the chief financial officer owned 90,192 shares in the company, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last quarter. 0.09% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $119.77 on Monday. The firm has a market cap of $296.13 billion, a price-to-earnings ratio of 16.45, a P/E/G ratio of 2.31 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The business has a fifty day simple moving average of $116.65 and a 200 day simple moving average of $102.06.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the previous year, the business posted $1.72 EPS. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is 46.70%.

Analysts Set New Price Targets

MRK has been the topic of several recent research reports. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Friday, February 13th. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Citigroup lifted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, March 20th. Finally, Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $127.13.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.